相关实验视频
Updated: Jul 23, 2025

06:41
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
12.5K
对于患有心血管不稳定的儿科急性呼吸窘迫综合征而言,有毒的体外膜氧化启动与血管不稳定性相关,与血管活性-内性得分的立即和持续下降有关
Daniel Chilcote1, Anant Sriram1, Julia Slovis1
1Division of Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, The Children's Hospital of Philadelphia, Philadelphia, PA.
概括
启动毒性体外膜氧化 (VV-ECMO) 在患有心血管不稳定的儿科急性呼吸困扰综合征 (PARDS) 患者中显著降低了血管活性-无热分数 (VIS),改善了他们的整体状况.
科学领域:
- 儿科重症监护医学 儿科重症监护医学
- 心血管生理学心血管生理学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 儿科急性呼吸困扰综合征 (PARDS) 往往涉及心血管不稳定性,需要显著的血管活性 - 非热带性支持.
- 静脉外体膜氧化 (VV-ECMO) 是严重呼吸衰竭的救生干预措施.
研究的目的:
- 调查VV-ECMO启动与患有PARDS和心血管不稳定症的儿科患者的血管活性-内托罗普评分 (VISs) 变化之间的关联.
主要方法:
- 在2009-2019年期间,对32名儿童 (1个月至18岁) 接受VV-ECMO治疗的PARDS的回顾性队列研究.
- 在VV-ECMO注射管之前和之后的24小时内,每小时分析血管活性-无热分数 (VISs),平均气道压力 (mPaw) 和血液气体值.
- 使用回归不连续性分析来评估管周围的即时变化.
主要成果:
- 启动VV-ECMO与VIS显著和立即下降有关 (强的p < 0.0001).
- 平均气道压力 (mPaw) 降低,而动脉pH值,度过多和氧和 (SpO2) 则在术后得到改善.
- 患者在VV-ECMO启动后经历了呼吸和/或代谢酸性减少.
结论:
- 启动VV-ECMO会立即和持续地减少患有PARDS和心血管不稳定症的儿科患者需要血管活性-异位支持的需求.
- 这种VIS的减少与改善的呼吸机制,氧化和酸平衡有关.
相关概念视频
Acute Respiratory Failure-IV
177
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
177
Cardiopulmonary Resuscitation IV: Pharmacological Management
26
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
26
Acute Respiratory Failure-II
278
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
278
Acute Respiratory Failure-III
227
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
227
Mechanical Ventilation III: Noninvasive Ventilation
152
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
Noninvasive Positive-Pressure Ventilation...
152
Acute Respiratory Failure-V
166
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
166

